Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Talphera, Inc. is a specialty pharmaceutical company developing innovative therapies for use in medically supervised settings. Its portfolio includes nafamostat-based product candidates for anticoagulation, antiviral, and inflammatory indications, targeting hospital and critical care markets. The company focuses on obtaining regulatory approvals, advancing clinical trials, and commercializing therapies that address unmet medical needs, leveraging proprietary formulations, patents, and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.